Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | PDE5A | O76074 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | PDE1A | P54750 | 1/20 | 0.41 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26966747 | 0.88 | PTGER1 (0.40) | FAAHPDE5APTGER1MEN1KMT2A | |
| SCHEMBL22451836 | 0.84 | BRD4 (0.49) | MRGPRX4BRD4 | |
| SCHEMBL29683735 | 0.84 | BRD4 (0.49) | MRGPRX4BRD4 | |
| SCHEMBL22451971 | 0.83 | MRGPRX4 (0.49) | MRGPRX4HPGDL3MBTL1 | |
| SCHEMBL22451837 | 0.83 | MRGPRX4 (0.49) | MRGPRX4BRD4 | |
| SCHEMBL15865609 | 0.80 | BRD4 (0.47) | MRGPRX4L3MBTL1BRD4 | |
| SCHEMBL12454120 | 0.79 | BRD4 (0.46) | MRGPRX4L3MBTL1BRD4 | |
| SCHEMBL3534571 | 0.78 | LMNA (0.55) | FAAHLMNAHPGDMEN1KMT2A | |
| SCHEMBL31288949 | 0.77 | PDE5A (0.61) | MRGPRX4PDE5APDE1APDE1BPDE1C | |
| SCHEMBL16108509 | 0.77 | LMNA (0.50) | FAAHLMNAHPGDPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220160908-A1 | CHELATORS AND METHODS OF MAKING AND USING SAME | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-05-26 | — | — | US | disclosed |
| US-20220160908-A1 | CHELATORS AND METHODS OF MAKING AND USING SAME | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-05-26 | — | — | US | disclosed |
| WO-2020186328-A1 | CHELATORS AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160908-A1 | CHELATORS AND METHODS OF MAKING AND USING SAME | TFRC, SLC40A1, FOLH1 | FAAH 2302/4885MRGPRX4 1100/4885PDE5A 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.